Ortek Therapeutics

Setting a new standard for optimal oral health

Ortek Therapeutics

Setting a new standard for optimal oral health

Roslyn Heights, NY
Health Tech
Ortek Therapeutics, Inc. is a medical device and functional food company that has commercialized novel products for the multi-billion dollar professional and consumer oral care markets. Our cutting-edge FDA cleared and patented early cavity detection device, the Ortek-ECD®, helps dental professionals diagnose and monitor cavities without radiation. The ECD can detect early tooth decay often missed by X-rays and other methods. Ortek’s BasicBites® are delicious, candy-like, sugar-free soft chews that are clinically shown to help maintain enamel health using innovative oral microbiome science. Our breakthrough technologies were developed and tested at Stony Brook University School of Dental Medicine. Ortek has entered into an exclusive worldwide license to the ECD patents that are owned by The Research Foundation for The State University of New York.

$63,368

raised
61
Investors
$22.7M
Valuation
$1.00
Price per Share
$250.00
Min. Investment
Common
Shares Offered
Equity
Offering Type
$1.07M
Offering Max
19
Days Left

$63,368

raised
61
Investors
$22.7M
Valuation
$1.00
Price per Share
$250.00
Min. Investment
Common
Shares Offered
Equity
Offering Type
$1.07M
Offering Max
19
Days Left

Stack Owner's Bonus & Rewards!

Members get an extra 10% shares in addition to rewards below!

Rewards

Get rewarded for investing more into Ortek Therapeutics:

$250+
Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.
$250+
Investment
$250+ | 1st Perk
Invest $250+ and receive a onetime $5 off for a single bag of BasicBites.
$1,000+
Investment
$1,000+ | 2nd Perk
Invest 1,000 and receive 5% bonus shares
$2,500+
Investment
$2,500+ | 3rd Perk
Invest $2,500 and receive 10% bonus shares
$5,000+
Investment
$5,000+ | 4th Perk
Invest $5,000+ and receive two free bags of BasicBites and 15% bonus shares
$10,000+
Investment
$10,000+ | 5th Perk
Invest $10,000 and receive four free bags of BasicBites and 20% bonus shares

Reasons to Invest

The Ortek-ECD is a revolutionary FDA cleared device that can help detect the earliest signs of tooth decay that X-rays often miss, while Ortek BasicBites are clinically shown to maintain enamel health by working with the body’s oral microbiome.
Tooth decay is the most prevalent chronic disease in the world, plus about one in four adults suffer from dry mouth.*
President and founder, Mitch Goldberg, has over 35 years of experience in the healthcare industry and previously co-founded Noven Pharmaceuticals, a publicly-traded company that was acquired for $428 million.

*Information provided by Research and Markets (source)

Overview


Seasoned pioneers in the oral care industry


Ortek has already conquered the expensive, time consuming and risky hurdles of commercializing our products. The internationally patented Ortek-ECD has been cleared by the FDA and is already used by hundreds of dentists in the US. The ECD utilizes breakthrough electronic conductance technology and does not use radiation. By painlessly touching a tooth’s surface, the ECD immediately and accurately helps dental professionals detect tiny cavities in our vulnerable back teeth; decay that is often missed by X-rays. 


Ortek’s BasicBites soft chews are clinically shown to help maintain enamel health using nature inspired oral microbiome technology. Both products are designed to help solve a major public health burden by the early diagnosis of tooth decay and taking an innovative approach to supporting enamel health.


Tooth decay is the world’s most common chronic disease (source)

and detecting it early is critical to avoid the pain of more advanced cavities, root canals, infections and tooth loss. Ortek has developed two revolutionary products to help people take back control of their oral health: The Ortek-ECD and BasicBites. 



An experienced and highly successful team leads Ortek. President and founder, Mitch Goldberg, has over 35 years of experience in the healthcare industry and was previously the co-founder, Executive VP and Director of Noven Pharmaceuticals, a two-person startup that became a highly profitable, publicly traded prescription drug company that was acquired for $428 million in cash. Goldberg is responsible for the clinical development, FDA clearance, commercial scale up, manufacturing and commercialization for the Ortek-ECD and for the commercialization of BasicBites. Ortek’s revolutionary technology is the result of its long-standing strategic alliance with The Research Foundation for The State University of New York and the world-renowned researchers in the Department of Oral Biology and Pathology at Stony Brook University School of Dental Medicine. 







The Problem


Close to one-third of the world's population suffers from tooth decay

Close to one-third of the world's population suffers from tooth decay and X-rays often fail to detect certain prevalent cavities in time (source). An estimated 2.3 billion people worldwide suffer from tooth decay in their permanent teeth and more than 530 million children suffer from cavities in their baby teeth.1 According to the CDC, about one-fourth of young children, half of adolescents, and more than 90% of adults have experienced tooth decay (source). 



CDC - Children’s Oral Health


Additionally, the back teeth (molars and premolars) are the sites most susceptible to cavities. These teeth have grooves, known as pits and fissures, that often trap cavity-causing bacteria (source). Dental X-rays and other methods often fail to detect cavities within the back teeth until there is advanced decay.2 



1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392: 1789–8583

2 Ricketts DN, Kidd EA, Smith BN, Wilson RF. Clinical and radio graphic diagnosis of occlusal caries: a study in vitro. J Oral Rehabil 1995; 22(1):15-20.



The Solution


Game-changing Technology -

A remarkable advance in early cavity detection and an innovative microbiome approach to supporting enamel health


ECD 

By painlessly measuring electrical conductance of enamel, the Ortek-ECD® can instantly detect cavities on the biting surfaces of the back teeth helping solve an everyday challenge for dental professionals. X-ray and other methods often miss early cavities on these extremely vulnerable surfaces until decay has advanced further into the tooth structure. The ECD is a small portable device that has a base unit with a digital display and a handpiece which utilizes disposable one-time use conductive stainless steel tips. 


*The above is a computer-generated rendering of a functioning product that is currently available on the market.


For dentists and hygienists, this amazing point-of-care diagnostic tool enhances their dental practice by improving patient outcomes, retaining patients, and attracting new ones. The ECD is easy to use, painless, generates immediate and accurate results, and is extremely affordable, providing a new profit center for dental offices that can provide them a return on investment in just days.

*Study published in the Journal of Clinical Dentistry (J Clin Dent 2019;30:1-5)


Comparison of the Detection of Early Occlusal Caries in Extracted Human Permanent Molar Teeth by Electrical Conductance and Biopsy Means


Robi Chatterjee, Research Scientist; Ana Maria Acevedo, Full Professor and Research Scientist

Israel Kleinberg, Distinguished Professor, Director of Translational Oral Biology Stony Brook University, School of Dental Medicine Department of Oral Biology and Pathology, Division of Translational Oral Biology Stony Brook, NY, USA  J Clin Dent. 2019 Jun,30 (2):1-5



Case Studies 

First case study: 

In this case, the patient had an obvious cavity on a section of their tooth (Site 1) and a slightly discolored or questionable spot (site 2).  X-rays failed to detect any cavity for site 2 and visual examination was inconclusive, making the dentist's treatment decision very difficult. 


Prior to initial preparation through the enamel layer, the ECD gave the following readings: site 1, 93 and site 2, 04.  In this case, the ECD scores proved extremely reliable relative to the depth of the cavities. More importantly, the ECD was very effective in detecting a cavity that may have normally gone untreated.



Second case study:

In this case, two adjoining teeth displayed discoloration possibly due to staining. X-rays were taken and there was no sign of cavities. This case was a diagnostic challenge for the dentist. 


Prior to initial preparation through the enamel layer, the ECD gave the following readings: 08 and 00. In this case, the ECD detected a cavity and the depth of the decay was over 2mm. The tooth with the 00 reading will be monitored, as the zero score by the ECD indicates that the stain or lesion did not extend through the enamel.



What Dental Professionals are Saying

Key opinion leaders Dr. Howard Glazer and Dr. Pamela Maragliano-Muniz recommend the Ortek-ECD.


*The above video was created and produced by the issuer prior to it determining to offer securities under Regulation CF. The discussion of investment return and image of ROI in the video applies to the issuer's customers and is not a guarantee of future performance or success.

*This testimonial may not be representative of the experience of other customers and is not a guarantee of future performance or success.


“The Ortek-ECD can pay for itself in just a few uses. No longer do we have to let our diagnosis of caries be a gut feeling. We can actually apply analytics.”

Joshua Austin, DDS, MAGD

Dental Economics, Pearls for your Practice


"I have used the ECD on numerous patients and it's extremely effective in detecting small cavitated lesions that may normally go untreated. The ECD scores are very reliable relative to the depth of the caries lesions." 

Derek Zimbardi, DDS

Dentistry Today, Quick Technique


"I have used the ECD on over 200 patients and I have never had a false positive. It's an amazing device that should be incorporated into nearly every dental practice. The ECD dramatically helps my patients and it can pay for itself in no time. I was so impressed with Ortek's university based technologies that I purchased stock in the company."

Brian Rosen, DDS


"I have found the Ortek-ECD device to be one of my most useful go-to tools for the early detection of pit and fissure caries. It is easy to use and a great complement to an intraoral camera for patient communication and discussion regarding their oral health status."

Neville Hatfield, DMD, MBS


*These testimonials may not be representative of the experience of other customers and is not a guarantee of future performance or success.



BasicBites 

BasicBites is are delicious sugar free, candy-like, soft chews designed for people who suffer from dry mouth and great for those with a “sweet tooth”. Recommended by leading dental professionals, these soft chews contain Ortek’s revolutionary oral microbiome technology and are available in two mouth-watering flavors, chocolate and caramel. Just two delicious BasicBites per day have been clinically shown to help maintain enamel health. BasicBites work differently than other oral care products. Renowned university researchers cracked nature’s code for supporting enamel health by discovering beneficial bacteria in dental plaque. These friendly bacteria produce buffers instead of harmful acids. The arginine bicarbonate in BasicBites nurtures and activates these beneficial pH-raising bacteria. This healthy and balanced oral pH environment allows the calcium carbonate in BasicBites to support the fortification of the enamel. By harnessing the power of nature, multi-action BasicBites immediately neutralizes harmful sugar acids, enriches enamel, and helps maintain a balanced and healthy oral pH environment. 





What Dental Professionals are Saying

*These testimonials may not be representative of the experience of other customers and is not a guarantee of future performance or success.


The Market


The oral care market is massive and growing and our products directly address its unmet needs 

The global dental services market was valued at $371.4 billion in 2020 and is expected to hit $698.8 billion by 2030 (source), while the worldwide dental equipment market was valued at $60.5 billion in 2019 and is predicted to reach $70.8 billion by 2024 (source). Globally, an estimated $298 billion is spent in direct costs associated with dental cavities, while an estimated $144 billion is spent on the indirect costs associated with dental cavities (source). 



There’s a tremendous global opportunity for the ECD. With approximately 200,000 dentists in the US and nearly 1 million dentists in the world, capturing 25% market share of this large targeted audience could generate over 150 million in sales. Additionally, the ECD tips are disposable and for one time use which could lead to additional ongoing revenue streams (source, source). 



The market for BasicBites is also vast. In 2020, the global oral care market was valued at $45 billion and is estimated to reach $53 billion by 2025 (source). In 2019, the worldwide functional food market had an estimated size of around $178 billion and is expected to reach around $268 billion by 2027 (source). Additionally, BasicBites are targeted for those individuals who suffer from dry mouth which is about one in four adults. The global market of dry mouth products was approximately $650 million in 2020 and projected to reach $825 million in 2027 (source). 



We believe ECD and BasicBites are unlike any other products in the dental and oral care markets. The ECD does not use radiation and helps dentists diagnose cavities in our vulnerable back teeth at the earliest possible stage. X-rays and other methods often fail to detect early cavities in these susceptible sites until there is more advanced decay. By unlocking the power of the oral microbiome, BasicBites takes a new approach to oral care. The breakthrough prebiotic microbiome technology in BasicBites is based on decades of university research investigating how mixed oral bacterial communities naturally interact to help maintain enamel health. 





Our Traction


Nationwide adoption from dental professionals and consumers

The Ortek-ECD and BasicBites technology were developed and tested at a leading US dental school. The ECD is FDA cleared and being used by hundreds of dentists throughout the US. In a published peer-reviewed clinical study, the ECD demonstrated 100% sensitivity and 93% specificity in detecting and diagnosing early cavities in back teeth.3 Ortek has obtained global patent protection for ECD in numerous key markets and has two patent-pending variants for BasicBites. 


BasicBites has been on the market since 2014 and is clinically shown to support and maintain enamel health. Recently, we finalized a formulation for a new patent-pending line extension of BasicBites. Cumulative sales of BasicBites have reached over $1 million to date, all with a limited marketing budget only focused on educating dental professionals.


3 Study published in the Journal of Clinical Dentistry (J Clin Dent 2019;30:1-5)



Through our long-standing strategic alliance with The Research Foundation for The State University of New York, Ortek also has worldwide exclusive licenses for two patents that naturally rebalance the body’s skin microbiome to suppress body odor and combat drug-resistant bacteria. These patented technologies are intended for topical administration for a wide array of over-the-counter and prescription products and Ortek is seeking strategic partners to further develop and commercialize these cutting-edge technologies. 


Why Invest


Together, we have the power to help millions optimize their oral health

Our vision for Ortek is to be a highly profitable global leader in the dental and oral care spaces, helping to alleviate a major global healthcare burden with our cutting-edge innovations. Our goal for the ECD is to have this breakthrough device in nearly every dental office throughout the world. For BasicBites, our mission is to target the huge dry mouth and consumer oral care markets across the US and the globe.


We are raising funds at this time so we can reach larger target audiences for the ECD and BasicBites. Our marketing programs will include social media, email, affiliate and influencer digital marketing strategies. Additionally, we will expand our professional print media, consumer and professional public relations campaigns, attendance at trade shows and further build our team of key opinion leaders. We will also leverage our existing professional and consumer database for repeat business, product referrals, and testimonials.


With the global dental services market expected to hit $698.8 billion by 2030 (source) and the global oral care market expected to reach $53 billion by 2025 (source), there is an ever-growing need for products like ours. And with tooth decay being the world’s most common chronic disease (source), Ortek has the power to truly make a difference. We’ve already conquered the expensive, time consuming and risky hurdles of commercializing our products. The Ortek-ECD is cleared by the FDA, patented internationally, and is now being successfully implemented by hundreds of dentists. BasicBites have been purchased by thousands of customers and we have only scratched the surface of the large dry mouth and oral care markets. We hope you will join us for this next phase of our growth, as we strive to truly make an impact improving oral health and create shareholder value.

Setting a new standard for optimal oral health – We are poised for growth



Quick Insert
Edit Link

In the Press

Dental Economics

No longer do we have to let our diagnosis of caries be a gut feeling. We can actually apply analytics.

Dental Economics

A portable electronic caries detection device with the power to find carious lesions before they're visible via radiograph.

Dentistry Today

The ECD is a valuable new tool that can help diagnose and monitor early cavitated lesions in pit and fissures that often go undetected by X-rays.

RDH Magazine

Imagine being able to chew a piece of candy that is actually good for your teeth.

Tale of two Hygienists

Early Caries Detection Made Easy with Ortek-ECD

Tale of two Hygienists

Who Knew Chewy Treats Could Be Good For Your Teeth!

Offering Summary


Company

:

Ortek Therapeutics, Inc.

Corporate Address

:

4 Expressway Plaza, Suite 206, Roslyn Heights, NY 11577

Offering Minimum

:

$10,000.00

Offering Maximum

:

$1,070,000.00

Minimum Investment Amount

(per investor)

:

$250.00











Terms


Offering Type

:

Equity

Security Name

:

Common Stock

Minimum Number of Shares Offered

:

10,000

Maximum Number of Shares Offered

:

1,070,000

Price per Share

:

$1.00

Pre-Money Valuation

:

$22,737,774.00











*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.

Voting Rights of Securities Sold in this Offering

Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.

Investment Incentives and Bonuses*

Time-Based:

Friends and Family Early Birds

Invest within the first 7 days and receive an additional 20% bonus shares.

Super Early Bird Bonus

Invest within the first 15 days and receive an additional 15% bonus shares.

Early Bird Bonus

Invest within the first 30 days and receive an additional 10% bonus shares.

Amount-Based:

$250+ | 1st Perk

Invest $250+ and receive a onetime $5 off for a single bag of BasicBites. 

$1,000+ | 2nd Perk

Invest 1,000 and receive 5% bonus shares

$2,500+ | 3rd Perk

Invest $2,500 and receive 10% bonus shares

$5,000+ | 4th Perk

Invest $5,000+ and receive two free bags of BasicBites and 15% bonus shares 

$10,000+ | 5th Perk

Invest $10,000 and receive four free bags of BasicBites and 20% bonus shares

*All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

Ortek Therapeutics, Inc will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $1.00 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $100. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors' eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

*Stacking perks only applies to the Owner's Bonus perk and Previous Backer perks. Time-based and Amount-based perks do not stack on top of each other, rather, the issuer will receive the greater of the two bonuses if they qualify for both.

Insider Investment Notice

Officers, directors, executives, and existing owners with a controlling stake in the company (or their immediate family members) may make investments in this offering. Any such investments will be included in the raised amount reflected on the campaign page.

Irregular Use of Proceeds

The Company will not incur any irregular use of proceeds.

Show More
Most recent fiscal year-end:
Prior fiscal year-end:
Total Assets
$1,406,235.00 USD
$2,014,889.00 USD
Cash And Cash Equivalents
$981,561.00 USD
$1,547,649.00 USD
Accounts Receivable
$0.00 USD
$931,347.00 USD
Short Term Debt
$28,530.00 USD
$22,638.00 USD
Long Term Debt
$0.00 USD
$0.00 USD
Revenues And Sales
$445,252.00 USD
$2,145,578.00 USD
Costs Of Goods Sold
$112,341.00 USD
$1,174,308.00 USD
Taxes Paid
$0.00 USD
$0.00 USD
Net Income
-$614,548.00 USD
-$230,189.00 USD

Risks

A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.


Updates

UPDATE: New Product Development Continues! Ortek to Launch New Oral Care Prebiotic Soft Chew with Added Sleep Promoting Ingredients

17 minutes ago

Closing in 19 Days!

Multi-Action BasicBites Bedtime™ Poised to Capitalize on the Multibillion Dollar Oral Care, Sleep Aid and Prebiotic Markets

Ortek has announced its plans to further extend its successful BasicBites® product with it’s upcoming introduction of BasicBites Bedtime™ soft chew. This revolutionary patent pending product combines Ortek's breakthrough microbiome oral care technology with a blend of Magnesium, Melatonin, and the amino acid L-theanine.

BasicBites Bedtime will further strengthen Ortek's ability to capitalize on opportunities in the global oral care, sleep aid and prebiotic markets.

It’s been estimated that sleep-related problems affect 50 to 70 million Americans of all ages and problems with sleep costing Americans $16 billion a year in medical expenses.* The U.S. sleep market was worth about $30.6 billion in 2019, and the total market of Rx and OTC sleep products is estimated at $2.1 billion in 2020.** The melatonin sleep supplements market is likely to grow its revenue to US$ 474 million in 2022 and is anticipated to cross US$ 1.059 billion by 2032.***

BasicBites Bedtime a one-of-a-kind oral care prebiotic and sleep aid with a patent pending formula which includes all of the following ingredients:

Arginine Bicarbonate and Calcium Carbonate which work together to create a healthy, balanced oral pH environment that protects teeth from harm caused by dry mouth, which affects 1 in 4 adults, and sugary foods and drinks. Arginine, an amino acid, nourishes the beneficial pH-raising bacteria discovered in dental plaque, resulting in immediate and sustained buffering on tooth surfaces that helps neutralize harmful plaque acids- a prebiotic process that harnesses the power of the oral microbiome. The calcium carbonate also enriches tooth enamel and bones and plays an important role in supporting the health of cardiovascular, muscular and nervous systems.

Magnesium which is an essential mineral that your body uses in hundreds of different biochemical reactions. Magnesium is required in sufficient amounts for all of your "feel-good" neurotransmitter systems to function properly. Magnesium deficiency, which has been estimated to affect approximately half of the U.S. population**** can result in a myriad of symptoms including chronic fatigue, depression, poor stress tolerance, irritability, restlessness, greater pain sensitivity, and sleep disturbances. Magnesium can help you sleep better by its ability to reduce tension and stress, and promote a calming effect on the brain and nervous system. Magnesium also helps regulate melatonin. The two forms in BasicBites Bedtime are organic magnesium (e.g. malate, taurate). In addition to being well-absorbed forms of magnesium, Magnesium Malate provides malic acid which is helpful for removing aluminum (a known neurotoxin) from the body and Magnesium Taurate provides taurine, a powerful antioxidant and neuroprotective amino acid, which has a calming and relaxing effect on the brain and nervous system.

Melatonin is a natural hormone that regulates your body’s sleep-wake cycle. The brain produces melatonin in response to darkness and it helps with the timing of your circadian rhythms (24-hour internal clock) and with sleep. Levels of melatonin increase in the evening when it’s dark to promote sleep and decrease in the light.

 

L-theanine is an amino acid that occurs naturally in tea. L-theanine promotes relaxation by supporting production of the calming neurotransmitter, GABA, which is also enhanced by magnesium and taurine.

As you can see, Ortek is not your typical med tech crowd-funded start-up. We’ve already conquered the expensive, time consuming and risky hurdles of commercializing our products with more on the way!

Closing Soon - Invest in Ortek Today

Sources
*
https://www.sleephealth.org/sleep-health/the-state-of-sleephealth-in-america/
**
https://blog.marketresearch.com/top-6-things-to-know-about-the-30-billion-sleep-aids-market
***
https://www.futuremarketinsights.com/reports/melatonin-sleep-supplements-market
****
https://www.pharmacytimes.com/view/study-half-of-all-americans-are-magnesium-deficient



Ortek's FDA cleared ECD helps us avoid the pain and expense of advanced tooth decay, root canals, infections, tooth loss and dental implants.

2 days ago

The Problem:
Close to one-third of the world's population suffers from tooth decay.* According to the CDC, about one-fourth of young children, half of adolescents, and more than 90% of adults have experienced tooth decay.**

Additionally, the back teeth (molars and premolars) are the sites most susceptible to cavities. These teeth have grooves, known as pits and fissures, that often trap cavity-causing bacteria.*** Dental X-rays and other methods often fail to detect cavities within the back teeth until there is advanced decay.

The Solution:

By painlessly measuring electrical conductance of enamel, the FDA cleared Ortek-ECD® can immediately detect tiny cavities on the biting surfaces of the back teeth that X-rays often miss– without utilizing radiation! This can dramatically improve patient outcomes by conserving tooth structure and help solve an everyday challenge for dental professionals. The ECD is a small portable device that has a base unit with a digital display and an audible alert. The ECD has a handpiece which utilizes disposable one-time use conductive stainless steel tips. The ECD demonstrated to be highly efficacious in a published peer-reviewed clinical study.****

The Opportunity:
There’s a tremendous global opportunity for the ECD. There are approximately 200,000 dentists in the US***** and nearly 1 million dentists in the world.****** The ECD is an FDA cleared Class II medical device and is patented in 20 countries including the U.S.

Our vision for Ortek is to be a highly profitable global leader in the dental and oral care spaces, helping to alleviate a major global healthcare burden with our cutting-edge innovations. Our goal for the ECD is to have this breakthrough device in nearly every dental office throughout the world.

Let's Revolutionize Oral Care Together!


Closing Soon — Invest in Ortek Today

Sources
*
https://time.com/3732925/one-third-world-tooth-decay/
**
https://www.cdc.gov/oralhealth/conditions/index.html
***
https://www.mayoclinic.org/diseases-conditions/cavities/symptoms-causes/syc-20352892
****
https://www.researchgate.net/publication/333031625_Comparison_of_the_Detection_of_Early_Occlusal_Caries_in_Extracted_Human_Permanent_Molar_Teeth_by_Electrical_Conductance_and_Biopsy_Means
*****
https://www.ada.org/resources/research/health-policy-institute/dentist-workforce
******
https://www.fdiworlddental.org


Ortek Offering Closing Soon!

6 days ago

The Perfect Pair for Superior Oral Care

Ortek has already conquered the expensive, time consuming and risky hurdles of commercializing our technologies. We believe our products have just scratched the surface in the multi-billion dollar oral care markets. 

Invest in Ortek today!


Closing Soon - Invest in Ortek today!

Ortek Completes Successful Routine FDA Inspection

7 days ago

Ortek is extremely proud to announce that we recently completed a successful routine U.S. Food and Drug Administration (FDA) inspection.

Our revolutionary Ortek-ECD® cavity detection system is an FDA cleared Class II medical device. Routine inspections are mandated by law every 2 years for companies selling Class II and Class III medical devices. These inspections focus on four major subsystems of our quality system; corrective and preventive actions (CAPA), design controls, management controls and production and process controls.

The positive conclusion to our routine FDA inspection is a testament to our commitment to maintaining the highest quality standards for our customers and investors.

Why Invest with Ortek?


Proven Commercialized Technology, Massive Market Opportunities, Experienced Management

The Ortek-ECD®:
• FDA cleared Class II Medical Device
• Patented in 20 countries
• Detects early tooth decay that X-rays often miss
• Does not utilize radiation
• Purchased by hundreds of dentists in the U.S.
• Named a Top 100 product by Dentistry Today
• Tooth decay is the world's most common chronic disease
• Early detection of cavities spares the pain and expense of advanced tooth decay, root canals, infections and tooth loss
• The global dental services market was valued at $371.4 billion in 2020 and is expected to hit $698.8 billion by 2030.** The worldwide dental equipment market was valued at $60.5 billion in 2019 and is predicted to reach $70.8 billion by 2024.***

BasicBites® Soft Chews:

• Contains our advanced oral microbiome technology
• Over $1 million in cumulative sales
• Immediately neutralizes harmful sugar acids, enriches enamel, and helps maintain a balanced and healthy oral pH environment
• Essential for the estimated one in four adults with dry mouth
• The global market for dry mouth products was approximately $650 million in 2020 and projected to reach $825 million in 2027.****
• In 2020, the global oral care market was valued at $45 billion and is estimated to reach $53 billion by 2025.*****

Robust Product Pipeline

BasicBites Synergy Plus - For additional oral care, bone and immunity support will be launched in Q4
• Additional BasicBites line extensions will be announced soon
• Ortek has exclusive licenses for two patents that naturally rebalance the body’s skin microbiome to suppress body odor and combat drug-resistant bacteria.

Experienced Management
• Ortek's President and Director have 75 years of healthcare experience.
• Mr. Goldberg and Mr. Sablotsky were founders of Noven Pharmaceuticals. Noven was a two-person transdermal drug delivery startup that went public and was eventually sold for $428 million in cash.******

As you can see, Ortek is not your typical med tech crowd-funded start-up.

Closing Soon! Invest in Ortek Today


Sources:
*https://www.researchgate.net/publication/272725948_Dental_Caries_The_Most_Common_Disease_Worldwide_and_Preventive_Strategies
**https://www.precedenceresearch.com/dental-services-market
***https://www.bccresearch.com/market-research/healthcare/dental-markets-furniture-equipment-materials-supplies.html
****https://www.researchandmarkets.com/reports/5303834/xerostomia-dry-mouth-therapeutics-global
*****https://www.globenewswire.com/news-release/2020/07/21/2064748/0/en/The-oral-care-oral-hygiene-market-is-projected-to-reach-USD-53-3-billion-by-2025-from-USD-45-8-billion-in-2020-at-a-CAGR-of-3-1.html
******
https://www.bizjournals.com/southflorida/stories/2009/07/13/daily20.html

Notice of Material Change in Offering

13 days ago

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the Ortek Therapeutics offering. Here's an excerpt describing the specifics of the change:


Issuer is extending campaign end date.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

Ortek Sells over 250 bags of BasicBites® in a Day

14 days ago

New Targeted Email Blast to Individuals with Dry Mouth a Huge Success
We are excited to report that we sold over 250 bags of BasicBites® in a single day this week resulting in net sales of approximately $10,000. We executed an incredibly successful email blast to individuals who suffer with dry mouth or xerostomia. BasicBites, which contains our revolutionary microbiome oral technology, has achieved cumulative sales over $1 million to date.
Why should you be excited? BasicBites, our breakthrough prebiotic candy-like chews, provide everyone with extra oral care support, but are essential for those individuals who suffer from dry mouth which is about one in four adults. The global market of dry mouth products was approximately $650 million in 2020 and projected to reach $825 million in 2027.*

We Have Just Scratched the Surface in Lucrative Oral Care Markets
In addition to the huge dry mouth target audience, the market for BasicBites is vast. In 2020, the global oral care market was valued at $45 billion and is estimated to reach $53 billion by 2025.** In 2019, the worldwide functional food market has an estimated size of around $178 billion and is expected to reach around $268 billion by 2027.***

Our Path to Success

We are raising funds at this time so we can reach with greater frequency target audiences for the Ortek-ECD®, our FDA cleared and globally patented early cavity detection device, and BasicBites. We recently hired a new digital marketing agency and our marketing programs include social media, email, affiliate and influencer digital marketing strategies. Additionally, we will expand our professional print media, consumer and professional public relations campaigns.

Ortek is not your typical med tech crowd-funded start-up.
We already are selling two products that have received rave reviews from our growing customer base of thousands of consumers and dental professionals – and more unique products are on the way!

With a proven track record of success, our prospects have never been brighter.

Invest in Ortek Today

Sources:
*
https://www.researchandmarkets.com/reports/5303834/xerostomia-dry-mouth-therapeutics-global
**
https://www.globenewswire.com/news-release/2020/07/21/2064748/0/en/The-oral-care-oral-hygiene-market-is-projected-to-reach-USD-53-3-billion-by-2025-from-USD-45-8-billion-in-2020-at-a-CAGR-of-3-1.html
***
https://www.alliedmarketresearch.com/functional-food-market

Ortek's FDA cleared ECD – "It's Magic"

20 days ago

Tooth decay is the world's most common chronic disease and most cavities occur on the biting surfaces of our back teeth. X-rays and other methods often fail to detect early decay on these extremely vulnerable sites. Dentists often encounter suspicious lesions on our back teeth that have no evidence of decay on X-rays, which creates a diagnostic challenge – To Drill or Not to Drill.



The Magic of the ECD in Action

In this case, the patient had an obvious cavity on a section of their tooth (site 1) and a slightly discolored or suspicious spot (site 2). X-rays failed to detect any cavity for site 2 and visual examination was inconclusive, making the dentist's treatment decision very difficult – Watch and wait for disease progression or drill.

Prior to initial preparation through the enamel layer, the ECD gave the following readings: site 1, 93 and site 2, 04. In this case, the ECD scores proved extremely reliable relative to the depth of the cavities. More importantly, the ECD was very effective in detecting a cavity that may have normally gone untreated.
This early diagnosis helped the patient avoid the pain and expense of more advanced decay!

As you can see, Ortek is not your typical med tech crowd-funded start-up. With a proven track record of success and more unique products in development, our prospects have never been brighter.

Invest in Ortek Today!

Ortek to Launch New Line Extension — BasicBites Synergy Plus™ to Capitalize on the Booming Multi-Billion Dollar Markets* for Prebiotics and Supplements

29 days ago

Additional New Line Extensions to be Announced Soon

We’re excited to announce that Ortek will extend our successful BasicBites® product line later this year when we introduce our patent-pending BasicBites Synergy Plus™ soft chew. This revolutionary product combines our breakthrough microbiome oral care technology with vital nutrients to help preserve tooth enamel and maintain healthy bones and immune and cardiovascular systems. 

Adding BasicBites Synergy Plus to our product portfolio will uniquely position Ortek to capitalize on opportunities in the global oral care, supplement and prebiotic markets which last year were valued at approximately $200 billion dollars.* We also are developing more BasicBites line extensions that we will announce soon.  

To support this new product, Ortek will continue to expand our marketing programs and leverage our loyal and growing customer base for BasicBites® and our breakthrough FDA-cleared and globally patented Ortek-ECD® device, which requires no radiation to detect early cavities that X-rays often miss. 

A One-of-a-Kind Prebiotic and Nutritional SupplementWith its revolutionary patent-pending formula, BasicBites Synergy Plus will include all of the following ingredients:

  • Arginine Bicarbonate and Calcium Carbonate which work together to create a healthy, balanced oral pH environment that protects teeth from harm caused by dry mouth, which effects 1 in 4 adults, and sugary foods and drinks. The calcium carbonate also enriches tooth enamel and bones and plays an important role in supporting the health of our cardiovascular, muscular and nervous systems.
     
  • K2VITAL®, a novel K2 MK-7 formula superior to other Vitamin K2 supplements. Vitamin K2 facilitates the transport and integration of calcium into bones and teeth. It helps maintain a normal calcium balance in arteries which may inhibit their calcification and prevent or slow the progression of arterial stiffness. This novel formulation from Kappa Bioscience maintains Vitamin K2’s potency in higher pH products such as BasicBites Synergy Plus.

  • Vitamin D3 which helps the body absorb calcium into the bloodstream and has a vital role in maintaining strong teeth and bones.  It also helps support a strong immune system and respiratory and neuromuscular functions and could play a role in maintaining cardiovascular health and metabolizing blood glucose.

Getting Ready for a Fast Takeoff

We expect to launch BasicBites Synergy Plus in Q4 and are amping up our marketing efforts now to make sure we’re ready to go on Day One. As we mentioned in an update last month, we recently began a marketing campaign with American Dental Association (ADA) that included Ortek ECD ads appearing in the Morning Huddle e-newsletter sent daily to the ADA’s 125,000 members. We’ve also hired a new digital agency to turbocharge our social media and digital marketing programs and, as with BasicBites, plan to offer our new product on Amazon and our website.

As you can see, Ortek is not your typical med tech crowd-funded start-up. We already are selling two products that have received rave reviews from our growing customer base of thousands of consumers and dental professionals. And, as our new BasicBites Synergy Plus product shows, we continually find new ways to take advantage of our proprietary technology. 

Welcome Aboard!

With a proven track record of success and more unique products in development, our prospects have never been brighter. 

Please join us as we grow and prosper by revolutionizing oral care. 

Invest in Ortek Today


*Sources
https://www.reportlinker.com/p04961844/Oral-Care-Oral-Hygiene-Market-by-Product-Toothpaste-Mouthwash-Dental-Floss-Teeth-Whitening-Breath-Freshener-Fixative-Distribution-Channel-Global-Forecast-to.html?utm_source=GNW

https://www.grandviewresearch.com/industry-analysis/dietary-supplements-market

https://www.grandviewresearch.com/industry-analysis/prebiotics-market

Another Reason Why The Ortek-ECD is Needed by Nearly Every Dental Office

about 1 month ago

We know tooth decay is the world's most common chronic disease. According to a new study published in The American Journal of Emergency Medicine source, there were 2 million dental-related visits to emergency rooms in the U.S. in 2018 and many visits were for toothaches.

To make matters worse, about 9 in 10 adults and approximately 6 in 10 children who presented at emergency departments with dental pain and without obvious signs of infection were prescribed antibiotics. About half of adult patients were prescribed opioids. The opioid and antibiotic prescription-writing habits in emergency rooms for dental pain raise serious issues due to concerns about antibiotic-resistant bacterial strains and the national opioid crisis. 

Ortek's FDA cleared ECD can detect, without the use of radiation, the early tooth decay that is often missed by X-rays and other methods. Early detection of cavities is critical to avoid the pain and expense of more advanced decay, root canals, infections, tooth loss and hopefully fewer emergency room visits for toothaches!

Ortek has already conquered the expensive, time consuming and risky hurdles of commercializing our technologies. We believe our products have just scratched the surface in the multi-billion dollar oral care market. Invest in Ortek today!

Ortek's ECD Named Top 100 Product for 2022 by Dentistry Today

about 1 month ago

We are excited to announce that Dentistry Today just named the Ortek-ECD® electronic cavity detection device a Top 100 Product for 2022. Earlier this year, Dentistry Today named the ECD a Top Innovative Product for 2022.

The ECD, Ortek's revolutionary electronic cavity detection device, has been cleared by the FDA and is patented in 20 countries including the U.S. The ECD immediately and accurately helps dental professionals detect tiny cavities — without the use of radiation — in our vulnerable back teeth where early decay is often missed by X-rays.

Tooth decay is the world's most common chronic disease. Early detection of cavities is critical to avoid the pain and expense of more advanced decay, root canals, infections and tooth loss.


We hope you will join us for this next phase of our growth as we strive to truly make an impact improving oral health.

Invest in Ortek Today

Ortek's ECD Proven Clinically and in Every Day Practice

about 2 months ago

In a published peer-reviewed clinical study, our FDA cleared and globally patented ECD early cavity detection system was shown to be 100% accurate in detecting early biting surface cavities. More importantly, the ECD has been embraced by hundreds of dental professionals.

Please review our clinical data and published reviews below. Unlike other emerging health tech companies, Ortek has already conquered the expensive, time consuming and risky hurdles of commercializing our products.

Tooth decay is the world’s most common chronic disease and detecting it early is critical to avoid the pain of more advanced cavities, root canals, infections and tooth loss. We are poised for growth! Let's transform oral care together! Invest in Ortek Today

Invest in Ortek Today

Ortek begins marketing campaign with American Dental Association

about 2 months ago

We are pleased to announce that we are now working with the American Dental Association (ADA) to promote our breakthrough oral care products- the FDA cleared Ortek-ECD® and BasicBites®.

For the next several months we will be advertising in the Morning Huddle, the ADA's daily e-newsletter that offers its members a connection to the latest news and trends affecting the dental profession. This new campaign augments our current marketing programs in other print and digital dental publications, including Dentistry Today and Dentistry IQ.

Please review our ECD ad in the Morning Huddle.


Game Changing Technology

Utilizing breakthrough electronic conductance technology, the FDA cleared and globally patented ECD can detect biting surface cavities at the earliest stages- without radiation! These small highly prevalent cavities are often missed by X-rays and other methods, and until now were a diagnostic challenge for dental professionals. 

The ECD is a game changer in early cavity detection- for patients and practitioners. The ECD can help save people from the pain and expense of more advanced decay that could possibly lead to root canals, infections and eventual tooth loss.

Ortek is setting a new standard in the multi-billion dollar oral care market.

We are poised for growth! Let's transform oral care together! Invest in Ortek Today

Ortek's ECD Presented at Gulf Shores Meeting of the Alabama Dental Association

2 months ago
Ortek's revolutionary FDA cleared early cavity detection system, the ECD, was recently part of a presentation made by Howard S. Glazer, DDS, FAGD at the Gulf Shores Meeting of the Alabama Dental Association. Dr. Glazer, an advisor to Ortek, is a Fellow and Past President of the Academy of General Dentistry.

 Watch Dr. Howard Glazer and Dr. Pamela Maragliano-Muniz, the Chief Editor of the Dental Economics family of publications, recommend the Ortek-ECD® to dental professionals.



Tooth decay is the world’s most common chronic disease. Ortek's FDA cleared and globally patented ECD is an amazing point-of-care diagnostic tool that helps solve a major worldwide public health burden by immediately detecting early biting surface cavities that X-rays often miss--and without radiation! 

Invest in Ortek Today!

Ortek's BasicBites® Achieves 500 "4.5 Star" Reviews on Amazon

2 months ago

We are excited to announce that our chocolate and caramel BasicBites® together now have 500 "4.5 Star" reviews on Amazon. Why are our customers so happy? Did you ever think you would be able to help support your enamel health simply by enjoying a delicious sugar free soft chew? Yes-you read that right. A candy-like chew that's actually good for your teeth.
BasicBites are a seriously delicious oral care breakthrough and recommended by leading dental professionals. Each 15 calorie sugar free chew contains our revolutionary prebiotic technology. BasicBites work differently than other oral care products. By unlocking the power of the oral microbiome, BasicBites immediately neutralize harmful sugar acids, enrich enamel and help maintain a balanced and healthy oral pH environment-the way nature intended.

For a better understanding of our amazing product and technology, please watch the Chairside Chat below with Michelle Strange, MSDH, RDH, an Ortek advisor who brings over 20 years of experience to her numerous roles in dentistry.


With BasicBites and the ECD, our breakthrough FDA cleared early cavity detection device, we have the power to transform oral health.

We hope you will join us for this next phase of our growth!

Invest in Ortek Today!

Ortek's BasicBites® are Backed by Decades of Oral Microbiome Research

2 months ago

BasicBites® - the candy-like soft chew that actually supports enamel health!

By unlocking the power of the oral microbiome, delicious sugar free BasicBites helps support enamel health the way nature intended. There are trillions of bacteria living inside and on our bodies and billions living in the oral cavity. It's well known that harmful bacteria in dental plaque break down sugars and produce acids that can damage teeth overtime.

Decades of university research led to the discovery of beneficial pH-raising bacteria that co-exist with the harmful acid generating bacteria in microbial ecosystems on tooth surfaces. Arginine, an amino acid, was isolated as the key substrate in saliva that these protective or commensal arginolytic bacterial strains metabolize to produce alkali or base. The arginine bicarbonate in BasicBites activates this natural pH-raising process in oral biofilms, resulting in immediate and sustained buffering that neutralizes harmful plaque acids and helps inhibit tooth demineralization. In this optimal pH environment, the calcium carbonate in BasicBites is available to enrich enamel and support the remineralization process.

Continued use of BasicBites can help the beneficial bacteria flourish while crowding out the harmful acid producing plaque bacteria – a natural prebiotic microbiome breakthrough! BasicBites do not kill bacteria or add new living strains of bacteria. Simply put, BasicBites activate your mouth’s natural defenses. Each sugar free chew is just 15 calories each and are essential if you have dry mouth or a sweet tooth.

Our new promotional flyer for dental professionals provides a great overview highlighting the decades of research supporting the BasicBites technology.

Unlike other emerging companies in the Health Tech industry, Ortek has already conquered the expensive, time consuming and risky hurdles of commercializing our products, including our FDA cleared and patented early cavity detection device, the Ortek-ECD.

Let's transform oral care together. Invest in Ortek Today!


Ortek's New ECD Print Advertisement

3 months ago

Please check out our new ECD print ad that is now running in Dentistry Today

Tooth decay is the world’s most common chronic disease and affects an estimated 2.3 billion people worldwide. The vast majority of cavities occur in the back teeth (molars and premolars). Without using radiation, the ECD painlessly measures the electrical conductance of enamel on these vulnerable sites and can immediately detect the earliest signs of tooth decay that X-rays often miss. The ECD is cleared by the FDA and is in use by hundreds of dentists in the U.S.

 For dental professionals, the ECD is easy to use, generates immediate and accurate results, and is extremely affordable -- current retail is $650.00. The ECD improves patient outcomes and provides a new profit center for dental offices. A win-win for patients and practitioners!

Unlike other emerging companies in the Health Tech industry, Ortek has already conquered the expensive, time consuming and risky hurdles of commercializing our products. Our breakthrough ECD cavity detection device has been cleared by the FDA, patented in 20 countries and has been purchased by hundreds of U.S. dental offices. Our BasicBites sugar free soft chews are commercially available and contain our revolutionary, nature inspired microbiome technology.

We hope you will join us for the next phase of our growth. Invest with Ortek Today

Ortek 10% Bonus Shares Ends Next Tuesday

3 months ago

Ortek's Early Bird 10% bonus shares ends next Tuesday, May 31st at 11:00 am (Eastern Time).

A special thank you to our early investors! We hope you have a happy and safe Memorial Day Holiday!

Let's transform oral care together. Invest in Ortek today!

Ortek's BasicBites featured at the Sjögren's 2022 Virtual National Patient Conference

3 months ago

BasicBites® was recently featured at the Sjögren's 2022 Virtual National Patient Conference. Sjögren's ("SHOW-grins") is a systemic autoimmune disease that affects the entire body. It is one of the most prevalent autoimmune diseases affecting an estimated 4 million Americans-mostly women. Many patients with Sjögren's experience dry mouth. Lack of saliva can damage teeth by creating an acidic oral environment that also favors harmful bacteria.

Ortek has been a proud supporter of the Sjögren's Foundation for many years. We believe BasicBites are essential for the millions of individuals with dry mouth. Please see our slide that was presented during the product showcase portion of the conference.

Breakthrough Oral Microbiome Science
Multi-action BasicBites coat and replenish teeth with a blend of vital protective nutrients - arginine bicarbonate and calcium carbonate - also found in healthy saliva. BasicBites immediately neutralize harmful sugar acids, enrich enamel and help maintain a balanced and healthy oral pH environment - a natural prebiotic microbiome breakthrough! BasicBites do not kill bacteria or add new living strains of bacteria. Simply put, BasicBites activate your mouth’s natural defenses the way nature intended!

A two-month supply of sugar free BasicBites is $39.95. BasicBites are available in mouthwatering chocolate and caramel flavors, and can be purchased online at the BasicBites website or on Amazon.


Ortek 15% Bonus Shares Ends Tomorrow

3 months ago

Ortek's Super Early Bird 15% bonus shares ends tomorrow at 11:00 am (Eastern Time).

A special thank you to our early investors! We have raised over $47,000 in less than two weeks.

Let's transform oral care together. Invest in Ortek today!

$45K Raised in Just Over a Week

3 months ago

We want to thank our first 35 investors who helped us raise $45K in just over a week. We greatly appreciate your support! Our Super Early Bird 15% bonus shares are still available for a limited time.

Unlike other emerging companies in the Health Tech industry, Ortek has already conquered the expensive, time consuming and risky hurdles of commercializing our products. Our breakthrough ECD cavity detection device has been cleared by the FDA, patented in 20 countries and has been purchased by hundreds of dental offices in the U.S.

Our BasicBites sugar free soft chews are commercially available and contain our revolutionary, nature inspired microbiome technology. BasicBites help support enamel health by nurturing the beneficial pH-raising bacteria discovered in dental plaque-a prebiotic process. BasicBites also supports the remineralization process. Sugar free BasicBites are 15 calories each and are available in mouthwatering caramel and chocolate flavors. Consumers and dental professionals can buy BasicBites from our website or on Amazon.


The ECD and BasicBites technologies were developed and tested by renowned researchers in the Department of Oral Biology and Pathology at Stony Brook University School of Dental Medicine.


Let's transform oral care together! Invest in Ortek Today

Exciting News!

3 months ago

Ortek's FDA Cleared Electronic Cavity Detection Device Receives 20th Global Patent



We are very excited to announce that the Brazilian Patent and Trademark Office has issued a patent for the Ortek-ECD®, our revolutionary electronic cavity detection device that can detect early tooth decay often missed by X-rays.

 With the addition of this newly issued patent in Brazil, the ECD is now covered by 20 issued patents in major global markets with patents now issued in:

Tooth decay is the world’s most common chronic disease and affects an estimated 2.3 billion people worldwide. The vast majority of cavities occur in the back teeth (molars and premolars). Without using radiation, the ECD painlessly measures the electrical conductance of enamel on these vulnerable sites and can immediately detect the earliest signs of tooth decay that X-rays often miss. The ECD is cleared by the FDA and is in use by hundreds of dentists in the U.S.



"This is another important milestone for Ortek as we expand the international patent portfolio for the ECD," said Ortek President Mitchell Goldberg. "Early detection of any disease is critically important, and the ECD allows dental professionals to catch tooth decay at a very early stage which helps patients avoid the pain, damage and costs associated with more advanced cavities."

We have already conquered the expensive, time consuming and risky hurdles of commercializing our products. Let's transform oral care together! Invest with Ortek today!

Great News for the Ortek-ECD!

3 months ago

A new feature article about our revolutionary FDA cleared and internationally patented early cavity detection device has just been published in Dentistry Today. The article  describes the amazing benefits of this breakthrough technology for patients, dental professionals and their practices.

Click to read full article.



Ortek Launches Equity Crowd-funding Campaign on StartEngine

3 months ago

Ortek Launches Equity Crowd-funding Campaign on StartEngine

Company is raising funds to support marketing for twobreakthrough oral care products

Early Ortek investors will receive bonuses

ROSLYN HEIGHTS, N.Y., May 11, 2022 -- Ortek Therapeutics, Inc., a leader in developing and commercializing novel oral care technologies, is now raising capital on StartEngine, the leading equity crowd-funding funding platform that has attracted 760,000 investors and has helped more than 760 companies raise $500 million.

Ortek will use funds raised on StartEngine to turbocharge multi-media marketing programs for its two revolutionary products – the Ortek-ECD® device, which is cleared by the FDA, and can detect early cavities that X-rays often miss, and BasicBites® delicious sugar free soft chews that use microbiome-based technology to help support enamel health. Bonuses are available for early investors. For details on Ortek’s equity crowd-funding offer, please visit startengine.com/ortek.

Tooth decay is the world’s most common chronic disease and affects an estimated 2.3 billion people worldwide. The vast majority of cavities occur in the back teeth (molars and premolars). Without using radiation, the ECD painlessly measures the electrical conductance of enamel on these vulnerable sites and can immediately detect the earliest signs of tooth decay that X-rays often miss. Early treatment can then help patients avoid the pain, damage and costs associated with more advanced cavities, which can lead to root canals, infections and tooth loss. The ECD is patented internationally and is used by hundreds of dental professionals in the U.S. and provides dental offices with a profitable revenue stream.
BasicBites are Ortek’s revolutionary sugar free soft chew product that is clinically shown to help maintain enamel health. BasicBites contain Ortek’s oral microbiome technology that helps support teeth from the harmful effects of dry mouth and sugary foods and drinks. BasicBites work differently than other oral care products. By harnessing the power of the oral microbiome, BasicBites immediately neutralize harmful sugar acids, enrich enamel and help maintain a balanced and healthy oral pH environment. Multi-action BasicBites coat and replenish teeth with a blend of vital nutrients that are also naturally found in the mouth – arginine, bicarbonate and calcium.

“The ECD and BasicBites are uniquely able to address widely prevalent unmet needs in dental care,” said Ortek President Mitchell Goldberg. “We see StartEngine as the launching pad for tremendous growth, and we have only begun to tap into the tremendous potential of these products.”

About Ortek
Ortek Therapeutics, Inc. is a global leader in developing and commercializing cutting-edge oral care technologies. For details on Ortek’s equity crowd-funding offer, visit https://www.startengine.com/ortek. For more information on the company, visit ortekinc.com

Insider Investment Notice

3 months ago

We're pleased to report that our insiders have invested $7500 into the offering.
We hope you join in as well! Invest in Ortek Therapeutics, Inc.


Please refer to the Company's offering materials for further information and refer to the Company's Risk Factors.

Show More Updates End of Updates

Comments ({{profileCtrl.startup.comments_count}} total)

{{profileCtrl.newComment.body.length}}/2500
Please sign in to post a comment.
Please use Updates for communications.
{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}